For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development expenses | 3,525,097 | 345,096.5* | 6,357,290 | 3,110,867 |
| General and administrative expenses | 3,424,832 | 2,134,113.5* | 3,003,636 | 2,055,191 |
| Total operating expenses | 6,949,929 | 2,479,210 | 9,360,926 | 5,166,058 |
| Loss from operations | -6,949,929 | -2,479,210* | -9,360,926 | -5,166,058 |
| Interest income | 111,757 | 76,769.5* | 78,426 | 79,697 |
| Grant income | 213,565 | 90,337.5* | - | - |
| Change in fair value of warrant liability | -254,955 | -1,291,159* | -379,311 | 260,602 |
| Loss on fair value of warrants over proceeds | - | - | - | 0 |
| Australian research and development incentives | - | - | - | 0 |
| Other income (expense) net | 580,277 | 1,458,266* | 457,737 | -180,905 |
| Net loss | -6,369,652 | -1,020,944 | -8,903,189 | -5,346,963 |
| Basic EPS | -0.14 | -0.031 | -0.27 | -0.18 |
| Diluted EPS | -0.14 | -0.031 | -0.27 | -0.18 |
| Basic Average Shares | 45,212,103 | 32,841,484 | 33,202,001 | 30,300,339 |
| Diluted Average Shares | 45,212,103 | 32,841,484 | 33,202,001 | 30,300,339 |
MAIA Biotechnology, Inc. (MAIA)
MAIA Biotechnology, Inc. (MAIA)